Serum bilirubin concentrations, type 2 diabetes and incident coronary heart disease

  • Tomoyuki KawadaEmail author
Letter to the Editor


Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.

Research involving human and/or animal participants

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed consent

For this type of study formal consent is not required.


  1. 1.
    Wang J, Wu X, Li Y et al (2017) Serum bilirubin concentrations and incident coronary heart disease risk among patients with type 2 diabetes: the Dongfeng-Tongji cohort. Acta Diabetol 54:257–264CrossRefGoogle Scholar
  2. 2.
    Uludag K, Oguzhan N, Arıkan T, Boz G (2018) Serum bilirubin level and its impact on the progression of chronic kidney disease. Int Urol Nephrol 50:1695–1701CrossRefGoogle Scholar
  3. 3.
    Li M, Li X, Liu Y et al (2018) Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia. Clin Chim Acta 486:156–161CrossRefGoogle Scholar
  4. 4.
    Jansen T, Hortmann M, Oelze M et al (2010) Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin. J Mol Cell Cardiol 49:186–195CrossRefGoogle Scholar
  5. 5.
    Gliozzi M, Malara N, Muscoli S, Mollace V (2016) The treatment of hyperuricemia. Int J Cardiol 213:23–27CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Hygiene and Public HealthNippon Medical SchoolTokyoJapan

Personalised recommendations